ProRx LLC
Has ProRx LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued ProRx LLC 2 warning letters naming semaglutide and tirzepatide, the latest dated Apr 7, 2026, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” openFDA also lists 14 drug recall reports for the firm naming semaglutide and tirzepatide.
FDA records in this index name ProRx LLC from Aug 22, 2024 to Apr 7, 2026. It is listed on FDA’s registered 503B outsourcing facility list: ProRx LLC, Exton, PA.
- Names in FDA records
- ProRx LLC; ProRx, LLC
- Type named in FDA records
- Compounding pharmacy, 503B outsourcing facility
- FDA warning letters
- 2
- Drug recall reports
- 14
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Apr 7, 2026
- 503B location
- Exton, PA
- 503B last inspection
- Sep 19, 2025
- Form 483 issued
- Yes
- Action on last inspection
- Warning Letter Issued 4/7/2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Apr 7, 2026 | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 4, 2025 | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Apr 7, 2026: … 27mg/3mL, 3mL in multidose vials and various lots of Semaglutide Injection multidose vials in multiple strengths, … 27mg/3mL, 3mL in multidose vials and various lots of Semaglutide Injection multidose vials in multiple strengths, … Full letter
- Mar 4, 2025: … 510 of the FDCA. 2. Your facility’s drug products, such as Semaglutide 5mg/2ml (2.5mg/ml) 2ml, Tirzepatide 60mg/3ml … Full letter
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Oct 15, 2025 | Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 841... | Lack of Assurance of Sterility | Class II | Ongoing | D-0115-2026 |
| Oct 15, 2025 | Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84... | Lack of Assurance of Sterility | Class II | Ongoing | D-0116-2026 |
| Oct 15, 2025 | Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 8413... | Lack of Assurance of Sterility | Class II | Ongoing | D-0118-2026 |
| Oct 15, 2025 | Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84... | Lack of Assurance of Sterility | Class II | Ongoing | D-0117-2026 |
| Oct 15, 2025 | Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139... | Lack of Assurance of Sterility | Class II | Ongoing | D-0114-2026 |
| Oct 15, 2025 | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 8413... | Lack of Assurance of Sterility | Class II | Ongoing | D-0119-2026 |
| Oct 15, 2025 | Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139... | Lack of Assurance of Sterility | Class II | Ongoing | D-0120-2026 |
| Aug 22, 2024 | Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01 | Lack of Assurance of Sterility | Class II | Ongoing | D-0650-2024 |
| Aug 22, 2024 | Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02 | Lack of Assurance of Sterility | Class II | Ongoing | D-0654-2024 |
| Aug 22, 2024 | SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01 | Lack of Assurance of Sterility | Class II | Ongoing | D-0652-2024 |
| Aug 22, 2024 | SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04 | Lack of Assurance of Sterility | Class II | Ongoing | D-0653-2024 |
| Aug 22, 2024 | Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01 | Lack of Assurance of Sterility | Class II | Ongoing | D-0651-2024 |
| Aug 22, 2024 | TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02 | Lack of Assurance of Sterility | Class II | Ongoing | D-0656-2024 |
| Aug 22, 2024 | TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01 | Lack of Assurance of Sterility | Class II | Ongoing | D-0655-2024 |
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
ProRX LLC, Exton, PA (503B)
4 listed actions, including 2 Form 483s and 2 warning letters (2024 to 2026).
| Document | |||
|---|---|---|---|
| Apr 7, 2026 | Warning letter | Warning Letter Issued 04/07/2026 | fda.gov |
| Sep 19, 2025 | Form 483 | 483 Issued 09/19/2025 | fda.gov |
| Mar 4, 2025 | Warning letter | Amended Warning Letter Issued 03/04/2025 | FDA copy (archived) |
| Aug 2, 2024 | Form 483 | 483 Issued 08/02/2024 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: ProRx LLC, Exton, PA.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Apr 7, 2026
- FDA warning letter, Mar 4, 2025
- openFDA drug recall enforcement reports
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.